Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $16 from $17 and keeps a Buy rating on the shares. The company reported a gross margin of 50% for Q4, up from 43% in Q3, owing to ongoing operational optimization, with further improvements expected over 2026 driven by internalization of lifileucel manufacturing at the company’s iCTC facility and optimization of R&D activities, the analyst tells investors in a research note. The firm adds however that the company’s pipeline continues to progress with multiple ongoing trials and initial evidence of lifileucel in soft tissue sarcomas looking encouraging.